Atosiban:
Atosiban, also known by its popular trade name Tractocile, is a medication used to inhibit the hormones oxytocin and vasopressin. This is delivered intravenously and serves as a labour repressor to halt premature birth. Originally developed by the pharmaceutical products company Ferring Pharmaceuticals in Sweden, it first appeared in literature in 1985 and has not yet been approved for commercialisation within the United States by the FDA. Although unavailable in the United States, atosiban was approved in the European Union in 2000, followed by a further 50 countries as of 2007. As such, atosiban manufacturers and atosiban suppliers are compelled to list their product for sale and wholesale to distributors across the global marketplace, where it can be found at varying price points, due in large part to the short duration of its patent.
Method of action of atosiban:
Atosiban is produced by manufacturers to reduce the frequency of uterine contractions to delay birth in adult women, alongside inducing uterine quiescence. As such, atosiban is a
nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist. Functioning through the inhibition of the oxytocin mediated release of inositol trisphosphate derived from the myometrial cell membrane. This prevents the release of stored calcium ions from the sarcoplasmic reticulum and the subsequent opening of the voltage-gated calcium ion channels. This ultimately prevents contractions of the uterine muscle by causing the described cytosolic calcium shut down, reducing the frequency of contractions and inducing uterine quiescence.
Form and dosage of atosiban:
As with all drugs, the form is dependent on specific manufacturers and suppliers. With atosiban typically being sold wholesale by distributors in forms including solutions for injection and concentrate for solutions for infusions. Atosiban is a controlled substance and should only be taken under the direct administration of a medical professional, with the recommended dose for adults with uncomplicated premature labour between 24 and 33 weeks of gestation initially being 6.75 mg over a 1 minute period by way of an intravenous infusion. Followed by 18 mg/hour for 3 hours or 6 mg/hour for up to 45 hours, with the maximum duration of treatment advised to not exceed 48 hours. All values are secondary to medical expertise and thus can vary.
Atosiban on Pipelinepharma:
The online Pipelinepharma marketplace, at the time of current writing, has 4 trusted atosiban manufacturers and atosiban suppliers with atosiban in their product list available for B2B order. These global manufacturers, suppliers, and distributors are situated in countries including the European Union and South Korea. All companies listed on our marketplace have been verified according to strict quality control by the Pipelinepharma team, this ensures a hassle-free sourcing experience with no dead ends.
Price of atosiban and how to buy:
The price of atosiban can vary significantly depending on a variety of factors including location, quantity, and manufacturer, alongside any established deals or agreements. For example, the NHS wholesale price in the United Kingdom is typically USD 23.28 per 7.5 mg/1 mL of atosiban. And may cost more for other organisations based on the desired quality and use. Although prices on the online Pipelinepharma marketplace are confidential and bespoke, manufacturers may choose to list the desired cost for their product to facilitate a quicker transaction. If so, this will be indicated alongside an ‘Accept’ and ‘Negotiate’ button, with a ‘Get offer’ button being displayed in the absence of a listed price.